arrow_back Back to App

Boosting US Antibiotic Production and Stockpiling Essential Drugs

This act aims to increase the production of critical antibiotics within the United States to ensure their constant availability for patients. Through this program, the government will support companies manufacturing these drugs domestically, reducing the risk of shortages. Additionally, the act provides for the creation of national stockpiles of these important medications.
Key points
The US government will allocate $500 million to support companies producing essential antibiotics within the United States.
Companies will receive grants to expand, upgrade, or build new antibiotic manufacturing facilities in the US.
The act allows for the purchase and stockpiling of domestically produced antibiotics, enhancing drug security.
A study will be conducted to identify which antibiotics are most crucial for US production and how this will affect consumer prices.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_1176
Sponsor: Sen. Smith, Tina [D-MN]
Process start date: 2021-04-15
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Onshoring Essential Antibiotics Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_1176.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-04-15.

What are the main provisions?

Key points include:

  • The US government will allocate $500 million to support companies producing essential antibiotics within the United States.
  • Companies will receive grants to expand, upgrade, or build new antibiotic manufacturing facilities in the US.
  • The act allows for the purchase and stockpiling of domestically produced antibiotics, enhancing drug security.
  • A study will be conducted to identify which antibiotics are most crucial for US production and how this will affect consumer prices.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Smith, Tina [D-MN].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health Public Investments Economy